Skip to content

Achieving Health in Emerging Adults With Diabetes (AHEAD) Program: A Clinical Trial Designed to Understand if Participation in a Clinical Program Developed Specifically to Support Emerging Adults With Type 1 Diabetes Leads to Improved Diabetes Outcomes.

Achieving Health in Emerging Adults With Diabetes (AHEAD) Study

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07292558
Acronym
AHEAD Program
Enrollment
306
Registered
2025-12-18
Start date
2025-12-15
Completion date
2028-12-31
Last updated
2025-12-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 1 Diabetes

Keywords

Adolescent, Young adult, Emerging adult, Patient transfer, Health care transition, Transition readiness, Diabetes self-management, Diabetes distress

Brief summary

The goal of this study is to determine whether the Achieving Health in Emerging Adults with Diabetes (AHEAD) Program helps emerging adults with type 1 diabetes improve their blood glucose management during the transition from pediatric to adult care. Participants will be randomized to receive Usual Care or the AHEAD Program, which provides tailored support to emerging adults to build autonomy and competence to facilitate independent diabetes management. Researchers will compare changes in glycemia and participant-reported outcomes between groups.

Detailed description

Many emerging adults with type 1 diabetes find it difficult to maintain their blood glucose levels within the recommended range most of the time. This can increase their risk for serious short- and long-term diabetes-related health problems. Managing diabetes becomes especially difficult during the transition from pediatric care to adult care when emerging adults are expected to manage their condition on their own. The Achieving Health in Emerging Adults with Diabetes (AHEAD) Program was developed to support emerging adults with their transition to independence. It focuses on helping them build autonomy and competence needed to manage their diabetes independently. The program is based on self-determination theory and best practices for supporting successful health care transition to adult care. In this study, 306 emerging adults will be randomly assigned to either the AHEAD Program or Usual Care arms. Participants will have 6 clinic visits and complete surveys prior to their clinic visits. AHEAD participants will receive support from a team of diabetes providers who have expertise in supporting emerging adults living with diabetes every three months. Usual Care participants will continue to receive the diabetes care as they do currently every three months. Researchers will evaluate changes in glycemia and participant-reported outcomes (e.g., diabetes distress, transition readiness). The study will also assess the cost and cost-effectiveness of AHEAD, as well as factors related to its implementation.

Interventions

BEHAVIORALAHEAD Program

Participants will complete self-assessments around health care transition readiness and mental health prior to an AHEAD clinic visit. Emerging adults will then received tailored clinical support based on their self-assessments and work to build their autonomy and competence to manage their diabetes and health care independently with the support of their AHEAD providers.

Sponsors

Breakthrough T1D
CollaboratorOTHER
Seattle Children's Hospital
CollaboratorOTHER
University of Washington
CollaboratorOTHER
Kaiser Permanente
CollaboratorOTHER
University of British Columbia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
16 Years to 19 Years
Healthy volunteers
No

Inclusion criteria

1. 16-19 years of age 2. Have had type 1 diabetes ≥ 12 months 3. Had a recent HbA1c ≥7.0% 4. Currently receive outpatient diabetes care at a Seattle Children's Hospital Diabetes Clinic located in Bellevue, Everett, Federal Way, or Seattle 5. Are able to complete written surveys 6. Will be able to receive clinical care in WA State for the next 2 years

Exclusion criteria

1. Have had a pilot program AHEAD clinic visit 2. Most recent Usual Care diabetes visit was with a current AHEAD provider

Design outcomes

Primary

MeasureTime frameDescription
Hemoglobin A1c (HbA1c)From enrollment (baseline clinic visit: 0 months) to the end of intervention period (6th clinic visit: 15-24 months).HbA1c laboratory measurement.

Secondary

MeasureTime frameDescription
Diabetes DistressFrom enrollment (baseline clinic visit: 0 months) to the end of intervention period (6th clinic visit: 15-24 months).Diabetes distress will be assessed with the Problem Areas in Diabetes Scale -- Teen Version. Higher scores indicate higher diabetes distress (score: 14-84).
Diabetes-Specific Health Care Transition ReadinessFrom enrollment (baseline clinic visit: 0 months) to the end of intervention period (6th clinic visit: 15-24 months).Diabetes-specific health care transition readiness will be assessed with the Readiness Assessment of Emerging Adults with Type 1 Diabetes tool. Higher scores (mean topic area score: 1-5) indicate higher diabetes-specific transition readiness.
General Health Care Transition ReadinessFrom enrollment (baseline clinic visit: 0 months) to the end of intervention period (6th clinic visit: 15-24 months).General health care transition readiness will be assessed with the Transition Readiness Assessment Questionnaire. Higher scores (mean topic area score: 1-5) indicate higher transition readiness.
Diabetes Family ConflictFrom enrollment (baseline clinic visit: 0 months) to the end of intervention period (6th clinic visit: 15-24 months).Diabetes family conflict will be assessed with the Diabetes Family Conflict Scale. Higher scores indicate higher diabetes family conflict (score: 19-57).
RelatednessFrom enrollment (baseline clinic visit: 0 months) to the end of intervention period (6th clinic visit: 15-24 months).Relatedness will be measured using the Health Care Climate Questionnaire. Higher scores indicate more supportive health care practitioner(s) (score: 15-105).
Time In RangesFrom enrollment (baseline clinic visit: 0 months) to the end of intervention period (6th clinic visit: 15-24 months).Continuous glucose monitor sensor glucose measurements that are in range (70-180 mg/dL), above range (\>180 mg/dL), and below range (\<70 mg/dL).
Disordered eatingFrom enrollment (baseline clinic visit: 0 months) to the end of intervention period (6th clinic visit: 15-24 months).Disordered eating will be measured using the Disordered Eating Problem Survey - Revised. Higher scores indicate increase disordered eating behaviors (score: 0-80).
DepressionFrom enrollment (baseline clinic visit: 0 months) to the end of intervention period (6th clinic visit: 15-24 months).Depression will be measured using the Patient Health Questionnaire-9. Higher scores indicate higher depression severity (score: 0-27).
Generalized AnxietyFrom enrollment (baseline clinic visit: 0 months) to the end of intervention period (6th clinic visit: 15-24 months).Anxiety will be measured using the Generalized Anxiety Disorder-7 questionnaire. Higher scores indicate higher severity of anxiety (score: 0-21).
Social needsFrom enrollment (baseline clinic visit: 0 months) to the end of intervention period (6th clinic visit: 15-24 months).Social needs will be measured using the social needs questionnaire. Endorsement of financial insecurity, food insecurity, transportation challenges, and housing insecurity, will indicate higher social need(s) (score: N/A).
Autonomy Treatment Self-Regulation QuestionnaireFrom enrollment (baseline clinic visit: 0 months) to the end of intervention period (6th clinic visit: 15-24 months).Autonomy will be measured using the Treatment Self-Regulation Questionnaire. Higher scores indicate higher autonomy (score: 15-105).

Countries

United States

Contacts

Primary ContactBeth Loots, MPH, MSW
beth.loots@seattlechildrens.org206-884-4488
Backup ContactFaisal S Malik, MD, MSc
faisal.malik@bcchr.ca604-875-2117

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026